About Thermosome GmbH
Thermosome is a clinical biotech company focused on drug development that concentrates on targeted tumor therapy combined with immune system stimulation to improve cancer treatment. The core of the company is a novel, patent-protected approach to targeted tumor treatment that enables significantly increased local drug concentration and improved tumor penetration to achieve enhanced clinical treatment efficacy. Thermosome’s leading drug candidate THE001 is a thermosensitive liposomal formulation of the chemotherapeutic agent doxorubicin (DPPG2-TSL-DOX) and pursues a different mechanism of action than conventional liposomes. Thermosome’s technology enables intravascular drug release triggered by mild heat stimulation using clinically established hyperthermia devices. This results in up to 15-fold higher local drug concentration in the tumor and aims to improve clinical efficacy by creating a local boost at the desired site of action. These high local concentrations, which also reach poorly perfused areas, have the additional goal of overcoming drug resistance. This effect cannot be achieved with conventional doxorubicin administration due to systemic toxicity. Thermosome intends to further improve treatment efficacy through an additive immune response induced by regional hyperthermia. The first clinical indication for THE001 development is soft tissue sarcoma, where the company aims to improve the current treatment standard (free doxorubicin). Thermosome’s approach enables targeted tumor treatment independent of specific molecular targets and covers patient populations across all tumor subtypes. THE001 has further development potential in other anthracycline-sensitive solid tumors such as breast cancer, bladder cancer, or ovarian cancer.
Discover relevant articles, startups, and events from the ecosystem
Online: Holding structures: Implementation and benefits for startups
